



Keywords:

Introduction

0.31% 16.5% ()

drug delivery, diagnostics, and therapeutics. By leveraging the unique properties of nanoparticles, such as their small size, high surface area-to-volume ratio, and tunable surface chemistry, researchers are developing innovative solutions for targeted drug delivery, enhanced bioavailability, and controlled release. Furthermore, nanotechnology offers new avenues for personalized medicine through the development of nanoparticle-based diagnostics and theranostics. Despite the tremendous opportunities, several challenges remain, including regulatory hurdles, safety concerns, and scalability issues. This review highlights recent advancements, current trends, and future prospects of nanotechnology in pharmaceutical sciences, emphasizing its potential to transform healthcare and improve patient outcomes.

Discussion

Conclusion

References

1. Eilouti BD (2007) Models for the Management of Precedent-Based Information in Engineering Design. WMSCI 2007 Orlando Florida USA: 321-326.
2. Buthayna H (2009) Eilouti Design knowledge recycling using precedent-based analysis and synthesis models. Des Stud 30: 340-368.
3. Eilouti B (2009) Knowledge modeling and processing in architectural design Proceedings of the 3rd International Conference on Knowledge Generation. Des Stud 30: 340-368.
4. Gao J, Tian Z, Yan X (2020) Breakthrough Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14: 72-73.
5. Flexner C (1998) HIV-protease inhibitors N Engl J Med 338: 1281-1292.
6. Ghosh AK, Osswald HL (2016) Prato Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem 59: 5172-5208.
7. Fan HH, Wang LQ (2020) Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus. Model Chin Med J.
8. Gao J, Tian Z, Yan X (2020) Breakthrough Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14: 72-73.
9. Flexner C (1998) HIV-protease inhibitors N Engl J Med 338: 1281-1292.
10. Ghosh AK, Osswald HL (2016) Prato Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem 59: 5172-5208.